Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-Arterial Microdosing Proof-of-Concept (IAM-POC)
NCT02304211Phase 1Completed
- Sponsor
- Duke University
- Start
- Dec 2014
- Primary completion
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of human insulin in diabetes mellitus (DM), sponsored by Duke University. Primary endpoints: Glucose Plasma Levels at 2 hours and 18F-fluorodeoxyglucose Uptake at 2 hours. Started Dec 2014; status: completed.
02
Drugs
human insulin
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT02304211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02304211.